Bedtime ACEIs/ARBs Versus Morning ACEIs/ARBs for Reverting Non-dipping Hypertension
Primary Purpose
Hypertension, Non-Dipping
Status
Terminated
Phase
Phase 4
Locations
Hong Kong
Study Type
Interventional
Intervention
ACEi, ARB
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Patients who are taking an ACEI or an ARB
- >18 years of age
- Chinese and
- Received a diagnosis of primary HT.
Exclusion Criteria:
- Severe HT as defined by a clinic systolic BP ≥180 mmHg and/or diastolic BP ≥ 110 mmHg
- allergic reaction or intolerance to the current ACEI or ARB
- unable to provide consent
- pregnancy
- night-time worker
- occupational drivers since patients will be asked not to move during BP measurements, which may induce potential danger in driving
- taking anti-coagulants to avoid causing bruises when using ABPM
- known atrial fibrillation since ABPM use has not been validated in this group
- known hyperkalemia
- ABPM discovered hypotension (mean SBP < 100 and/or mean DBP < 60) because these patients may need to stop their medications
- Reported sleep time of <4 hours per night (at least seven readings are recommended during sleep for an ABPM recording to be valid, and a sleeping time < 4 hours is unlikely to generate valid results).
Sites / Locations
- Lek Yuen Clinic
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
intervention
control
Arm Description
ACEIs or ARBs will be switch to be taken before bedtime
ACEIs or ARBs will be taken in the morning as usual
Outcomes
Primary Outcome Measures
proportion of non-dipping in each group as measured by ambulatory BP machines(ABPM)
the ABPM - An ApneABP (Meditech, Hungary) will be used in the study. non-dipping is defined as lack of more than 10% drop in SBP during sleep when compared to awake BP. The sleep duration and time are defined by actigraphy (Actigraph, model GT9X-BT)
Secondary Outcome Measures
mean awake and asleep SBP/DBP of 48-hour duration as assessed by ABPM
feasibility of the intervention as assessed by dropout rate
The trial is deemed feasible and a larger similar study can be conducted if: (i) ≤30% of ND patients drop out from the study
Full Information
NCT ID
NCT03284099
First Posted
September 13, 2017
Last Updated
April 7, 2020
Sponsor
Chinese University of Hong Kong
1. Study Identification
Unique Protocol Identification Number
NCT03284099
Brief Title
Bedtime ACEIs/ARBs Versus Morning ACEIs/ARBs for Reverting Non-dipping Hypertension
Official Title
Is Bedtime Administration of ACEIs and ARBs More Effective for Reverting Non-dipper Status Than Morning Administration for Non-dipping Hypertension in Hong Kong Primary Care? A Pilot Study
Study Type
Interventional
2. Study Status
Record Verification Date
April 2020
Overall Recruitment Status
Terminated
Why Stopped
No funding obtained. The ABPM machines are being used for another project
Study Start Date
December 1, 2017 (Actual)
Primary Completion Date
December 31, 2019 (Actual)
Study Completion Date
December 31, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chinese University of Hong Kong
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
5. Study Description
Brief Summary
Background: Non-dipping (ND), defined as a <10% decrease in blood pressure (BP) during sleep, is an independent significant predictor of cardiovascular outcome in hypertensive patients. A few anti-hypertensive medications, including angiotensin receptor blockers (ARBs) and angiotensin converting enzyme inhibitors (ACEIs), may normalize dipping if administered at night. Chinese data are scarce and there are no prospective studies on cardiovascular outcomes in Chinese patients.
Aim: To determine if the bedtime administration of ACEIs and ARBs is more effective at normalizing ND than morning administration. As a pilot project, the feasibility of recruiting hypertension patients in primary care for ambulatory blood pressure monitoring (ABPM) and conducting a clinical trial will be evaluated such that future larger randomized trials can be planned to determine treatments for ND.
Method: Fifty patients diagnosed with essential hypertension who are receiving either ACEIs or ARBs and diagnosed with ND will be randomized to take ACEIs or ARBs either early morning or before bedtime. A follow-up 48-hour ABPM will be performed after 4-6 weeks to examine post-treatment changes in BP and ND status.
Outcome: The primary outcome of this proposed study is the proportion of ND at 6 weeks; secondary outcomes will include (i) mean awake and asleep SBP/DBP of 48-hour duration (ii) feasibility of this pilot study will be assessed by recruitment and dropout rates during the study period.
Potential: This pilot study will provide the basis for a future larger randomized controlled study to further examine the treatment for ND in primary care.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Non-Dipping
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Care ProviderInvestigator
Allocation
Randomized
Enrollment
4 (Actual)
8. Arms, Groups, and Interventions
Arm Title
intervention
Arm Type
Experimental
Arm Description
ACEIs or ARBs will be switch to be taken before bedtime
Arm Title
control
Arm Type
Active Comparator
Arm Description
ACEIs or ARBs will be taken in the morning as usual
Intervention Type
Drug
Intervention Name(s)
ACEi, ARB
Intervention Description
To take the ACEis or ARBs before bedtime instead of in the morning
Primary Outcome Measure Information:
Title
proportion of non-dipping in each group as measured by ambulatory BP machines(ABPM)
Description
the ABPM - An ApneABP (Meditech, Hungary) will be used in the study. non-dipping is defined as lack of more than 10% drop in SBP during sleep when compared to awake BP. The sleep duration and time are defined by actigraphy (Actigraph, model GT9X-BT)
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
mean awake and asleep SBP/DBP of 48-hour duration as assessed by ABPM
Time Frame
6 weeks
Title
feasibility of the intervention as assessed by dropout rate
Description
The trial is deemed feasible and a larger similar study can be conducted if: (i) ≤30% of ND patients drop out from the study
Time Frame
1 year (assessed after the whole study)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients who are taking an ACEI or an ARB
>18 years of age
Chinese and
Received a diagnosis of primary HT.
Exclusion Criteria:
Severe HT as defined by a clinic systolic BP ≥180 mmHg and/or diastolic BP ≥ 110 mmHg
allergic reaction or intolerance to the current ACEI or ARB
unable to provide consent
pregnancy
night-time worker
occupational drivers since patients will be asked not to move during BP measurements, which may induce potential danger in driving
taking anti-coagulants to avoid causing bruises when using ABPM
known atrial fibrillation since ABPM use has not been validated in this group
known hyperkalemia
ABPM discovered hypotension (mean SBP < 100 and/or mean DBP < 60) because these patients may need to stop their medications
Reported sleep time of <4 hours per night (at least seven readings are recommended during sleep for an ABPM recording to be valid, and a sleeping time < 4 hours is unlikely to generate valid results).
Facility Information:
Facility Name
Lek Yuen Clinic
City
Hong Kong
Country
Hong Kong
12. IPD Sharing Statement
Plan to Share IPD
Undecided
IPD Sharing Plan Description
to decide after end of trial
Learn more about this trial
Bedtime ACEIs/ARBs Versus Morning ACEIs/ARBs for Reverting Non-dipping Hypertension
We'll reach out to this number within 24 hrs